Cyclopamine

Catalog No.S1146 Synonyms: 11-deoxojervine

Cyclopamine Chemical Structure

Molecular Weight(MW): 411.62

Cyclopamine is a specific Hedgehog (Hh) signaling pathway antagonist of Smoothened (Smo) with IC50 of 46 nM in TM3Hh12 cells.

Size Price Stock Quantity  
USD 147 In stock
USD 270 In stock
USD 370 In stock
USD 470 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

4 Customer Reviews

  • (A) The effects of cyclopamine (10 μM) in pancreatic cancer cell invasion. The number of migrated cells was quantified by counting the number of cells from 10 random fields at 200 magnification. (B) The effects of cyclopamine on the expression of EMT-related molecules E-cadherin and vimentin, and Hh pathway-related proteins SMO and Gli-1 were analyzed by Western blotting following treatment of MiaPaCa-2 and Panc-1 with SDF-1 for 48 h in the presence or absence of the SMO inhibitor cyclopamine. Normal culture was used as a negative control. (C) The EMT-related molecules Ecadherin and vimentin mRNA levels, and Hh pathway-related genes at mRNA level were analyzed by real-time RT-PCR following treatment of MiaPaCa-2 and Panc-1 with SDF-1 for 48 h in the presence or absence of the SMO inhibitor Cyclopamine. Normal culture was used as a negative control.

    Cancer Lett 2012 322, 169-176. Cyclopamine purchased from Selleck.

    (A)[3H]thymidine incorporation assay of B16F10 melanoma cells treated with DMSO or cyclopamine after incubation with SA-CM from WT and Cav1KO dermal fibroblasts. Representative phase-contrast images of B16F10 cells treated with SA-CM from WT and Cav1KO fibroblasts with cyclopamine are shown on the right. Similar experiments (B) were done with A-375 cells incubated with SA-CM from hTBJ1-shCtrl and hTBJ1-shCAV1 cells.

    Cancer Res 2012 72, 2262-74. Cyclopamine purchased from Selleck.

  • (A) Exogenous Shh peptide (500 ng/mL) for 72 hours promoted expansion of CD34+ cells and CD34- cells, cyclopamine (10 μM) for 72 hours induced apoptosis of CD34+ cells and CD34- cells, as measured by 3-(3,5-dimethylthiazol-2-yl)-2,5-diphenyl-tetrazoliumbromide (MTT) assay, n =4, bars, standard deviation. *Statistically significant compared with CD34+ cells. (B) Exogenous Shh peptide (500 ng/mL) promoted cell expansion after 48 hours and cyclopamine (10 μM) induced cell apoptosis within 24 hours measured by MTT assay (n=6).

    Exp Hematol 2012 40, 418-27. Cyclopamine purchased from Selleck.

    For MTT assays, cells (2,000 ~ 5,000 cells/well) were subcultured into 96-well plates according to their growth properties. Cell proliferation was assayed at 72 hr after treatment of Cyclopamine by adding 20 μl of 5 mg/ml 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) solution per 100 μl of growth medium. After incubating for 3-4 h at 37°C, the media were removed and 150 µl/well of MTT solvent (either absolute DMSO or isopropanol containing 4 mM HCl and 0.1% Nonidet-40) was added to dissolve the formazan. The absorbance of each well was measured by ELx808 (BioTek, Winooski, VT) or Wallac Victor2 (Perkin-Elmer Life Sciences, Boston, MA) Microplate Reader. Viable cells are presented as percent of control, vehicle-treated cells.

     

     

    Dr. Yong-Weon Yi from Georgetown University Medical Center. Cyclopamine purchased from Selleck.

Purity & Quality Control

Choose Selective Hedgehog/Smoothened Inhibitors

Biological Activity

Description Cyclopamine is a specific Hedgehog (Hh) signaling pathway antagonist of Smoothened (Smo) with IC50 of 46 nM in TM3Hh12 cells.
Targets
Smoothened [1]
(TM3Hh12 cells)
46 nM
In vitro

Cyclopamine inhibits the Hedgehog signaling pathway with an IC50 of 46 nM, and blocks the activity of human Smo receptor expressed in CHO-K1 cells in [3H]Hh-Ag binding assay with an IC50 of 280 nM. [1] Cyclopamine significantly inhibits Hedgehog pathway activity in a dose-dependent manner in gut-derived tumor cell lines expressing Patched (PTCH) mRNA, and induces growth inhibition of those tumor cell lines by 75-95% at the concentration of 3 μM, but ineffective towards the colon tumor cells without PTCH mRNA expression, suggesting the effects of Cyclopamine treatment are Hedgehog pathway related rather than generally cytotoxic. [2] By blocking Hedgehog signaling through direct interaction with Smo, Cyclopamine (10 μM) inhibits the proliferation of SMOhigh Cyclopamine-responsive cell lines L3.6sl and Panc 05.04 by 75-80%, and increases the apoptosis by 2.5- to 3.5-fold, without affecting the BxPC3-SMOlow cell line. [3] Cyclopamine treatment significantly decreases of Snail mRNA and increasea E-cadherin transcripts in the E3LZ10.7 cell line. Independent of inhibition of cell growth, Cyclopamine treatment significantly inhibits the invasive phenotype of Hedgehog-dependent L3.6pl cells, causing a >500-fold reduction in the number of transmigrating cells, but not that of the Hedgehog-independent cell line Panc-1. [4]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
OS-RC-2 NHW1UFRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV[3fFJCUUN3ME21Mlg3PjZizszN MY\TRW5ITVJ?
DOHH-2 MofBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH[xeGlKSzVyPUmuN|U3QDlizszN M13oS3NCVkeHUh?=
no-10 NU\LT|JsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MW\JR|UxRTlwOUCzPUDPxE1? Mk\FV2FPT0WU
LS-513 M4TuXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWfKd412UUN3ME2xNU4{PTR5IN88US=> NV;GNWtPW0GQR1XS
ALL-PO NWLZVWhPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoPlTWM2OD1zMT63O|M1KM7:TR?= MmjMV2FPT0WU
8-MG-BA NEewSmFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYj3TItqUUN3ME2xN{4yOTJ|IN88US=> MVLTRW5ITVJ?
RPMI-8402 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXvRcpprUUN3ME2xOU45PTN5IN88US=> Mn3TV2FPT0WU
EoL-1-cell NEm4bmxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVO1VJRpUUN3ME2xPE42QTR6IN88US=> NEPwNGRUSU6JRWK=
NALM-6 Mnf0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIjaRWVKSzVyPUG5MlAyPjdizszN NIKyOWlUSU6JRWK=
DEL MkHNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3nEOGlEPTB;MkCuNVQ4OSEQvF2= NULIcGw4W0GQR1XS
SR MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEnmZVNKSzVyPUKzMlY4OTVizszN NVvsVHg5W0GQR1XS
697 NUDwR4UxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4HzTGlEPTB;Mk[uOlE2PSEQvF2= MmjqV2FPT0WU
COLO-829 Mn:2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M120SGlEPTB;Mk[uPFQ5OyEQvF2= NX7qRWtHW0GQR1XS
EVSA-T MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGGxcHZKSzVyPUK3MlU2PjFizszN M4Oz[nNCVkeHUh?=
ATN-1 NHjIbppIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUnJR|UxRTNzLkKzNlkh|ryP M172S3NCVkeHUh?=
L-363 NIfxNYtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWrJR|UxRTNzLke0OlEh|ryP MV3TRW5ITVJ?
LAMA-84 NXPaZmV5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NE[5UnBKSzVyPUOyMlUzOTFizszN M4WwcnNCVkeHUh?=
NOS-1 NXP3d4dlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVfJR|UxRTN2LkK5OVYh|ryP M{PoV3NCVkeHUh?=
BB30-HNC M2XzRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NETj[HhKSzVyPUO0MlM{ODZizszN NEK4Oo1USU6JRWK=
BC-1 NGXk[WlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnixTWM2OD1|Nz65O|Q3KM7:TR?= NVHOT2lRW0GQR1XS
IST-SL2 NHvkOHRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2i4cWlEPTB;M{iuNlI1KM7:TR?= M1Pyb3NCVkeHUh?=
D-392MG NInNTJpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGPaeGxKSzVyPUSwMlIzOTVizszN NUPqfnR3W0GQR1XS
no-11 NHnETWZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{jifGlEPTB;NECuOVUzOSEQvF2= MljLV2FPT0WU
LC4-1 NU[4SIJ1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXi4cWtzUUN3ME20NE45PzF4IN88US=> Mn3qV2FPT0WU
A388 M3;tcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWjrdHBoUUN3ME20Nk42QDR6IN88US=> NV33eJBEW0GQR1XS
NTERA-S-cl-D1 M1flVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHTXUmZKSzVyPUSyMlcxPzRizszN NILIPYVUSU6JRWK=
CESS M1;B[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYPJR|UxRTR2LkKyN|Ih|ryP MYTTRW5ITVJ?
RS4-11 NF33bHRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVjk[WZWUUN3ME20PU4xQTN6IN88US=> NXnwU2E2W0GQR1XS
MS-1 M17sOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NITOT4lKSzVyPUWwMlk{PTFizszN NWfGbXN2W0GQR1XS
CTV-1 NXvnb4x5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4TjU2lEPTB;NUGuNFc1KM7:TR?= NI\0WWNUSU6JRWK=
D-502MG NXnE[2d4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3ra[mlEPTB;NUGuOlI4OSEQvF2= MYLTRW5ITVJ?
ML-2 NVv1S2lbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mm\kTWM2OD13Mj65NVk2KM7:TR?= MojFV2FPT0WU
SK-NEP-1 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkjWTWM2OD13Mz6zPVI{KM7:TR?= NYj2XoIzW0GQR1XS
LOXIMVI NF\wV|ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NILRZpFKSzVyPUWzMlU5QDRizszN MXTTRW5ITVJ?
DJM-1 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml3STWM2OD13Nj6zN|kyKM7:TR?= MmfiV2FPT0WU
GI-1 Mn7SS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MluxTWM2OD13Nj62NVQ6KM7:TR?= M2C1RnNCVkeHUh?=
IST-MES1 M{jEbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmnnTWM2OD14MD61OFk{KM7:TR?= NVTROI9JW0GQR1XS
MV-4-11 NHrGOYxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3fJXWlEPTB;NkCuOlU{QCEQvF2= M4HWSXNCVkeHUh?=
OVCAR-4 NXLtWpFDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkDzTWM2OD14Mz61OlU4KM7:TR?= MofMV2FPT0WU
KE-37 NYPMbWtqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3zLOGlEPTB;Nk[uNlY3QCEQvF2= MYTTRW5ITVJ?
D-542MG NG\mS4pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV\JR|UxRTZ6LkSxN|Uh|ryP NHfsOXpUSU6JRWK=
MHH-PREB-1 MmmyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1O2TmlEPTB;N{KuPFQ1OSEQvF2= NGfQWWNUSU6JRWK=
MRK-nu-1 MnPMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NICxXmtKSzVyPUezMlQ4ODVizszN MoSyV2FPT0WU
D-247MG NWPPNJhIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlqxTWM2OD15Mz61OFQzKM7:TR?= MnfjV2FPT0WU
OCI-AML2 NXT0UoNRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NE\Yc3VKSzVyPUe2Mlk{PjlizszN Mk[2V2FPT0WU
LP-1 Mo\XS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MULJR|UxRTh{Lki3N|Eh|ryP NYDUR41uW0GQR1XS
HCC1599 MmDXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1jQO2lEPTB;OESuNlg{PyEQvF2= NXzRUpNqW0GQR1XS
KARPAS-45 NVvOPHFHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3\4dmlEPTB;OESuOlk6OiEQvF2= M4X0UXNCVkeHUh?=
BE-13 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3zWZ2lEPTB;OUmuNFQ4PyEQvF2= MmHFV2FPT0WU
GCIY NYTMcmk3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXfaUlV7UUN3ME25PU4xQTV2IN88US=> MkHHV2FPT0WU
BV-173 M4jEOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXvJR|UxRTFyMD6zNlUh|ryP NUXzR4tFW0GQR1XS
LB2518-MEL NIXMdnJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGP0cIZKSzVyPUGwNE44QDlizszN NHr0dWFUSU6JRWK=
KS-1 NHTwbVNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4nHT2lEPTB;MUCxMlY{QSEQvF2= MoPCV2FPT0WU
MOLT-16 M4TZSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVvJR|UxRTFyND65PFYh|ryP MVTTRW5ITVJ?
NCI-H1770 NUTEUWZmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NI\RRpNKSzVyPUGwPE44QDRizszN NWHtbHdHW0GQR1XS
NCI-H82 M1K5VGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoLLTWM2OD1zMUCuPVc3KM7:TR?= NGLDW2FUSU6JRWK=
NCCIT NYeyfnNwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmC4TWM2OD1zMUKuOVI6KM7:TR?= Mkn2V2FPT0WU
KALS-1 MlS0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYLKOZhYUUN3ME2xNVUvQTRzIN88US=> Mk\pV2FPT0WU
LB2241-RCC MlvYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NITuco9KSzVyPUGxOk43PzlizszN NVixdWh6W0GQR1XS
HH MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV:2U3h1UUN3ME2xNVcvOzl3IN88US=> NHGyUW9USU6JRWK=
HD-MY-Z M3rxbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2PIRWlEPTB;MUG4MlQ5QCEQvF2= NFTaVmRUSU6JRWK=
EB-3 Ml;xS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3HNc2lEPTB;MUKzMlA6PCEQvF2= NUXGZXFoW0GQR1XS
BL-70 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVfJR|UxRTF{Mz6xNlch|ryP MkD6V2FPT0WU
K-562 Ml3nS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmPhTWM2OD1zMk[uNlQ2KM7:TR?= MUjTRW5ITVJ?
HT-144 M2[4Tmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYPqfIFoUUN3ME2xN|MvOTZ2IN88US=> MXrTRW5ITVJ?
PF-382 NFHxTFVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmjFTWM2OD1zM{SuN|YyKM7:TR?= NGjVVWdUSU6JRWK=
RPMI-8226 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVTJR|UxRTF|NT6wOFUh|ryP MnjkV2FPT0WU
NCI-H1355 Ml2wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWjQXHdUUUN3ME2xN|UvPTh5IN88US=> MWnTRW5ITVJ?
LXF-289 M3Hu[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYnCSJJLUUN3ME2xN|kvPzhzIN88US=> MYjTRW5ITVJ?
NCI-H69 M3:2cWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NInMb4JKSzVyPUG0Nk46OzJizszN NEjx[2pUSU6JRWK=
SK-MEL-1 M4j2WWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NU\kR4N7UUN3ME2xOFcvOTNizszN Mlv4V2FPT0WU
KARPAS-299 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{TvbWlEPTB;MUS5MlEzKM7:TR?= NGrzXZlUSU6JRWK=
GB-1 M2jyTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFu0[mhKSzVyPUG0PU4{OjJizszN MXnTRW5ITVJ?
CMK NV[y[Gh1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXfJR|UxRTF2OT61NVUh|ryP Mn7zV2FPT0WU
MPP-89 M2HndGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4S0T2lEPTB;MUW2MlA{PSEQvF2= MnTiV2FPT0WU
KU812 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFK4N2VKSzVyPUG2NU46ODJizszN NIrqfoRUSU6JRWK=
REH NELjTHNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWnJR|UxRTF4Mj6xNlUh|ryP M3rrbXNCVkeHUh?=
NEC8 MkXyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGmyS2JKSzVyPUG2OU4xOjZizszN NF3DZ3hUSU6JRWK=
KP-N-YS NUTjXG1xT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYfJR|UxRTF4OD6zPVUh|ryP NVXpfXB6W0GQR1XS
Ramos-2G6-4C10 MlXDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1;jOGlEPTB;MU[5MlkyPSEQvF2= M37UdHNCVkeHUh?=
Becker MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF\rPFhKSzVyPUG3OE4yQCEQvF2= NVrTfWlVW0GQR1XS
LB647-SCLC MoLhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVS5VG9bUUN3ME2xO|UvQDR3IN88US=> M4jVeHNCVkeHUh?=
LU-139 Ml7OS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWHJR|UxRTF5OD6wNVkh|ryP M1OwTnNCVkeHUh?=
QIMR-WIL NYHRfZZET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVXJR|UxRTF5OT62OFYh|ryP NEP2XlZUSU6JRWK=
NCI-H1395 NXm3b4puT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWjPSIlxUUN3ME2xO|kvQTl4IN88US=> MWnTRW5ITVJ?
NOMO-1 NHK4bVVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1vqUmlEPTB;MUiyMlg2KM7:TR?= MojkV2FPT0WU
GI-ME-N NIXrO3VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEXq[GZKSzVyPUG4O{46PjlizszN M4\S[3NCVkeHUh?=
KMS-12-PE NGfYOolIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYTJR|UxRTF6OT6yO|Mh|ryP MWjTRW5ITVJ?
Daudi MoW2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVT5bVdXUUN3ME2xPVEvOTJ6IN88US=> NYfhbWZUW0GQR1XS
LB996-RCC M{e0Omdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NG[0fpBKSzVyPUG5NU43QTlizszN NUfWO2gxW0GQR1XS
NCI-H2107 NIC4VZZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmnZTWM2OD1zOUOuO|M6KM7:TR?= NH;BN|hUSU6JRWK=
SK-PN-DW NFXjS|dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1;iemlEPTB;MUm0MlcyQSEQvF2= MVfTRW5ITVJ?
MC-CAR NYHmbmJbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{j0d2lEPTB;MkCyMlI2OyEQvF2= MXLTRW5ITVJ?
SNB75 NVPjNHF[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV\JR|UxRTJ{MT65OEDPxE1? M4TaUXNCVkeHUh?=
ES4 NHPoOWhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NE[xW5JKSzVyPUKyN{44QDNizszN NWqxTJdyW0GQR1XS
KARPAS-422 M37XXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFzTTmdKSzVyPUKyPE4{PTJizszN NWHNboZSW0GQR1XS
NCI-H1648 NFjaNWVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3jRNWlEPTB;MkK5MlQ5QSEQvF2= Mne3V2FPT0WU
ES6 NHq5bWZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2rHbGlEPTB;MkO5MlQ{KM7:TR?= NIT5O45USU6JRWK=
KNS-81-FD MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVPsbohlUUN3ME2yOFEvOTl5IN88US=> MnPaV2FPT0WU
JAR NVW0UpBXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX;JR|UxRTJ3Nj6yNlUh|ryP NYjz[JJDW0GQR1XS
NB1 M4H3N2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVHJR|UxRTJ4MD61NVYh|ryP NX;Gfm5vW0GQR1XS
D-336MG NYTXdIhJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUfnbpJYUUN3ME2yOlAvPjl6IN88US=> NXPx[G86W0GQR1XS
BC-3 Mlr3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV\CVpRQUUN3ME2yOlUvOTd6IN88US=> Moj0V2FPT0WU
HCC2218 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFXU[lRKSzVyPUK2Ok41OTVizszN MUPTRW5ITVJ?
TE-9 MlzYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn20TWM2OD1{Nk[uOlI4KM7:TR?= MnnFV2FPT0WU
LB1047-RCC NXOxdY5VT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYnrUodxUUN3ME2yOlYvPzV|IN88US=> M2jW[HNCVkeHUh?=
CTB-1 NV6xVZc6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mnv2TWM2OD1{NkmuPVc{KM7:TR?= Mk\LV2FPT0WU
NB7 NYfYRY05T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXewTG9CUUN3ME2yO|Eh|ryP M2n6R3NCVkeHUh?=
ST486 MofrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWTxSZNvUUN3ME2yO|cvPDF{IN88US=> MoXIV2FPT0WU
HCC1187 MmTLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXzJR|UxRTJ6Mj64NVEh|ryP NVK5d2FuW0GQR1XS
NCI-SNU-16 NYW4bZh4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGHjVm5KSzVyPUK4OE4zPDhizszN Mo\TV2FPT0WU
COR-L279 NXHKTphRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml25TWM2OD1{OUGuOVg1KM7:TR?= NYHs[|FoW0GQR1XS
ES8 NXfYNmpWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX3JR|UxRTJ7ND6xPFIh|ryP MlSxV2FPT0WU
U-698-M NGLJeI1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUP4RoZ7UUN3ME2yPVgvOjR|IN88US=> NUjvVItoW0GQR1XS
HEL M1LnUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYPJR|UxRTNyOT6xOFkh|ryP NWj2cVlyW0GQR1XS
KINGS-1 NH:4OHRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXT1SIJmUUN3ME2zNVAvPjd2IN88US=> MkPEV2FPT0WU
KY821 MofqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIHZdlJKSzVyPUOzOk42QTVizszN MnXBV2FPT0WU
MZ1-PC MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NY\YUIFuUUN3ME2zOFUvPjF6IN88US=> NXOwUZdUW0GQR1XS
LS-411N M3nJPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXXJR|UxRTN3ND62OkDPxE1? MojlV2FPT0WU
SIG-M5 M1fETWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF\OSWxKSzVyPUO1PU44QDJizszN NXr0R5puW0GQR1XS
HT MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnS3TWM2OD1|NkeuO|EyKM7:TR?= M3HKUnNCVkeHUh?=
HC-1 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MojLTWM2OD1|NkeuO|g4KM7:TR?= MmC2V2FPT0WU
NCI-H1694 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1\Hd2lEPTB;M{eyMlk{PCEQvF2= NG[4[mJUSU6JRWK=
BB65-RCC MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlXTTWM2OD1|N{[uNlQ2KM7:TR?= MV\TRW5ITVJ?
HAL-01 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFrrSmlKSzVyPUO3PU45OzhizszN MWDTRW5ITVJ?
ARH-77 MknRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlmyTWM2OD1|OUSuNFA5KM7:TR?= NV;tW5JjW0GQR1XS
MZ7-mel MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIPKe|lKSzVyPUO5O{4zOzNizszN NIi4TlJUSU6JRWK=
SIMA MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M37RfGlEPTB;NECzMlk{OyEQvF2= M373OXNCVkeHUh?=
DG-75 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml7uTWM2OD12MUWuOlk5KM7:TR?= M4rTZXNCVkeHUh?=
HUTU-80 NGn1PXFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVLJR|UxRTRzOT6xPFUh|ryP MVzTRW5ITVJ?
KNS-42 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmHRTWM2OD12MkWuPFE2KM7:TR?= MXvTRW5ITVJ?
SH-4 M4HJOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2fKS2lEPTB;NEK3MlU3PSEQvF2= NWTHT4F3W0GQR1XS
L-540 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml:1TWM2OD12M{GuNFMyKM7:TR?= NEnaSFVUSU6JRWK=
NB10 M3TvdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlnLTWM2OD12NEGuNlM1KM7:TR?= NV7i[JpVW0GQR1XS
ES1 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVHacIRvUUN3ME20OVIvPzV|IN88US=> M{HwW3NCVkeHUh?=
KMOE-2 NULVWpU3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkTFTWM2OD12NU[uO|EyKM7:TR?= MkixV2FPT0WU
MC116 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHjkdG5KSzVyPUS1PE4yOTZizszN MYLTRW5ITVJ?
RCC10RGB NILDTFZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2PjTmlEPTB;NE[wMlAxPSEQvF2= M4ficnNCVkeHUh?=
RL95-2 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHT3R|FKSzVyPUS2NE4zOzdizszN NHmyeW1USU6JRWK=
Raji NF;UdIhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2KzUmlEPTB;NE[4MlE1OyEQvF2= M3;KWnNCVkeHUh?=
CAS-1 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHSxZZZKSzVyPUS3Nk4xPzNizszN NFT5e41USU6JRWK=
Calu-6 NWO0cWljT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXjJR|UxRTR5NT6yOlUh|ryP NVflXm9qW0GQR1XS
KG-1 NIPYSnpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEWyfW9KSzVyPUS3PE41PCEQvF2= NYXXTJRTW0GQR1XS
LB771-HNC NUCzb2RJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3;xfmlEPTB;NEiyMlI{OiEQvF2= MofvV2FPT0WU
ACN MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnnOTWM2OD12OUOuOVk6KM7:TR?= MkXLV2FPT0WU
KM12 NYj5eZBrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHPXdotKSzVyPUS5Ok42QDlizszN M3nMV3NCVkeHUh?=

... Click to View More Cell Line Experimental Data

In vivo Administration of Cyclopamine at dose of 50 mg/kg/day for 22 days eradicates the HUCCT1 xenografts in mice with no obvious adverse effects. [2] Cyclopamine treatment at dose of 1.2 mg for 7 days induces significant apoptosis of tumor cells and decreases the tumor mass by 50-60% in Panc 05.04- and L3.6sl-derived tumors, respectively, but not in the BxPC3-SMOlow tumors. [3] Administration of Cyclopamine alone profoundly inhibits tumor metastases in xenografts of E3LZ10.7 and L3.6pl, and completely abrogates metastases when in combination of gemcitabine. [4]

Protocol

Kinase Assay:[1]
+ Expand

Hedgehog cell assay:

This assay measures the end stage of the Hh signaling pathway, that is, the transcriptional modulation of Gli, using Luciferase as readout (Gli-Luc assay). Cyclopamine is prepared for assay by serial dilution in DMSO and then added to empty assay plates. TM3Hh12 cells (TM3 cells containing Hh-responsive reporter gene construct pTA-8xGli-Luc) are resuspended in F12 Ham's/DMEM (1:1) containing 5% FBS and 15 mM Hepes pH 7.3, added to assay plates and incubated with Cyclopamine for approximately 30 minutes at 37 °C in 5% CO2. 1 nM Hh-Ag 1.5 is then added to assay plates and incubated at 37 °C in the presence of 5% CO2. After 48 hours, either Bright-Glo or MTS reagent is added to the assay plates and luminescence or absorbance at 492 nm is determined. IC50 value, defined as the inflection point of the logistic curve, is determined by non-linear regression of the Gli-driven luciferase luminescence or absorbance signal from MTS assay vs log10 (concentration) of Cyclopamine using the R statistical software pack
Cell Research:[2]
+ Expand
  • Cell lines: SEG1, OE33, KYAE, KYSE180, SNU1, AGS, SNU16, NCI-N-87, HUCCT1, PANC1, PL5, PL6, BXPC3, HS766T, KYSE150, GBD1, DLD1, and HCT116
  • Concentrations: Dissolved in DMSO, final concentration 3 μM
  • Incubation Time: 4 days
  • Method: Cells are exposed to Cyclopamine in 96-well plates. Cell viability is measured by MTS (soluble tetrazolium salt) assay. Viable cell mass is determined by optical density measurements at 490 nm (OD490) at 2 and 4 days using the CellTiter96 colorimetric assay. Relative growth is calculated as OD (day 4)﹣OD (day 2)/OD (day 2).
    (Only for Reference)
Animal Research:[2]
+ Expand
  • Animal Models: Athymic (nude) mice inoculated subcutaneously with HUCCT1 cells
  • Formulation: Dissolved in DMSO, and diluted in saline
  • Dosages: 50 mg/kg/day
  • Administration: Subcutaneous injection
    (Only for Reference)

Solubility (25°C)

In vitro DMF 10 mg/mL warmed (24.29 mM)
Ethanol 2 mg/mL warmed (4.85 mM)
DMSO Insoluble
In vivo Add solvents individually and in order:
10% DMSO+30% PEG 300+5% Tween 80+ddH2O
1mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 411.62
Formula

C27H41NO2

CAS No. 4449-51-8
Storage powder
Synonyms 11-deoxojervine

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    How to reconstitute the compound for in vivo use in mice?

  • Answer:

    One paper dissolved this drug in DMSO, and diluted in saline: Berman DM, et al. Nature, 2003, 425(6960), 846-851. Alternatively, you can try this vehicle: 10% DMSO+30% PEG 300+5% Tween 80+ddH2O for P.O. When preparing the solution, please dissolve the compound in DMSO clearly first. Then add PEG300 and Tween, after they mixed well, dilute with water.

Hedgehog/Smoothened Signaling Pathway Map

Hedgehog/Smoothened Inhibitors with Unique Features

Related Hedgehog/Smoothened Products

Tags: buy Cyclopamine | Cyclopamine supplier | purchase Cyclopamine | Cyclopamine cost | Cyclopamine manufacturer | order Cyclopamine | Cyclopamine distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID